[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100199247":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":24,"locations":25,"responsibleParty":36,"collaborators":24,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":24,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":24,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":61,"whyStopped":24,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Hanmi Pharmaceutical Company Limited","INDUSTRY",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"HCP1104","EXPERIMENTAL",[12],"Drug: HCP1104 \u002F Mulex Tab. and Airtal Tab.",{"label":14,"type":15,"description":16,"interventionNames":17},"Mulex Tab. and Airtal Tab.","ACTIVE_COMPARATOR","Eperisone Hydrochloride and Aceclofenac",[12],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","HCP1104 \u002F Mulex Tab. and Airtal Tab.","HCP1104 \u002F Eperisone plus Aceclofenac",[9,14],null,[26],{"facility":27,"status":24,"city":28,"state":24,"zip":24,"country":29,"countryCode":24,"cosmosGeoPoint":30,"geoPoint":35,"contacts":24},"Asan Medical Center","Seoul","South Korea",{"type":31,"coordinates":32},"Point",[33,34],126.9784,37.566,{"lat":34,"lon":33},{"type":37,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100199247","phase-1-partial-replicated-crossover-clinical-study-to-compare-pharmacokinectic-characteristics-of-eperisone-hydrochloride-and-aceclofenac-with-hcp1104-treatment-to-those-of-co-administration-of-eperisone-hydrochloride-50mg-tablet-and-aceclofenac-100mg-tablet-in-healthy-adult-male-volunteers-100199247",false,"NCT01869985","Partial Replicated Crossover Clinical Study to Compare Pharmacokinectic Characteristics of Eperisone Hydrochloride and Aceclofenac With HCP1104 Treatment to Those of Co-administration of Eperisone Hydrochloride 50mg Tablet and Aceclofenac 100mg Tablet in Healthy Adult Male Volunteers","A Randomized, Open-label, Single Dose, 3-sequence and 3-period Partial Replicated Crossover Clinical Study to Compare Pharmacokinectic Characteristics of Eperisone Hydrochloride and Aceclofenac With HCP1104 Treatment to Those of Co-administration of Eperisone Hydrochloride 50mg Tablet and Aceclofenac 100mg Tablet in Healthy Adult Male Volunteers","Inclusion Criteria:\n\n* Healthy male volunteers, age between 20 and 45\n* BMI of \\>20kg\u002Fm2 and \\\u003C28kg\u002Fm2 subject\n* Informed of the investigational nature of this study and voluntarily agree to participate in this study\n\nExclusion Criteria:\n\n* Use of any prescription medication within 14 days prior to Day 1\n* Use of any medication within 7 days prior to Day 1\n* Participation in another clinical study within 60 days prior to start of study drug administration",true,"MALE","20 Years","45 Years",{"count":50,"type":51},30,"ACTUAL","INTERVENTIONAL",[54],"PHASE1","The purpose of this study is to evaluate pharmacokinetics and safety after oral administration of HCP1104 and Eperisone Hydrochloride plus Aceclofenac.",[57],"Healthy",[9,59,60],"Eperisone Hydrochloride","Aceclofenac","COMPLETED","2014-03-08",{"date":64,"type":65},"2014-03-11","ESTIMATED",{"date":67,"type":24},"2013-08",{"date":69,"type":51},"2014-01",{"name":5,"class":6},1]